Tipelukast

Tipelukast
Names
	IUPAC name 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenyl)sulfanylpropoxy]-2-propylphenoxy]butanoic acid
	Other names KCA 757; MN-001
Identifiers
CAS Number	125961-82-2;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:177735;
ChEMBL	ChEMBL2104988;
DrugBank	DB12435;
KEGG	D06659;
PubChem CID	9893228;
UNII	08379P260O;
CompTox Dashboard (EPA)	DTXSID00925325 ;
	InChI InChI=1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33) Key: KPWYNAGOBXLMSE-UHFFFAOYSA-N;
	SMILES CCCC1=C(C=CC(=C1OCCCC(=O)O)C(=O)C)OCCCSC2=C(C(=C(C=C2)C(=O)C)O)CCC;
Properties
Chemical formula	C29H38O7S
Molar mass	530.68 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Tipelukast (KCA 757 or MN-001) is a sulfidopeptide leukotriene receptor antagonist with suspected anti-inflammatory properties. It is developed by MediciniNova.^[1]^[2]^[3]^[4]

References

^ "MN-001 - MediciNova, Inc". medicinova.com. Retrieved 3 December 2023.
^ Rajasekaran, Mahadevan; Locke, Kenneth W.; Parsons, C. Lowell (August 2006). "MN-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model". BJU International. 98 (2): 430–434. doi:10.1111/j.1464-410X.2006.06274.x. PMID 16879690. S2CID 44269457.
^ Matsuda, Kazuko; Iwaki, Yuichi (December 2014). "MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model: LB-28". Hepatology. 60 (6): 1283A. ISSN 0270-9139.
^ Bascom, R.; Hitz, K.; Dimmock, A.E.F.; Makhay, M.; Dojillo, J.; Matsuda, K. (May 2020). "Description of Protocol to Evaluate MN-001'S (tipelukast) Efficacy, Safety and Tolerability in Subjects with Idiopathic Pulmonary Fibrosis". A37. Ild Therapy I. pp. A1493. doi:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1493. S2CID 225921518.

[1] "MN-001 - MediciNova, Inc". medicinova.com. Retrieved 3 December 2023.

[2] Rajasekaran, Mahadevan; Locke, Kenneth W.; Parsons, C. Lowell (August 2006). "MN-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model". BJU International. 98 (2): 430–434. doi:10.1111/j.1464-410X.2006.06274.x. PMID 16879690. S2CID 44269457.

[3] Matsuda, Kazuko; Iwaki, Yuichi (December 2014). "MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model: LB-28". Hepatology. 60 (6): 1283A. ISSN 0270-9139.

[4] Bascom, R.; Hitz, K.; Dimmock, A.E.F.; Makhay, M.; Dojillo, J.; Matsuda, K. (May 2020). "Description of Protocol to Evaluate MN-001'S (tipelukast) Efficacy, Safety and Tolerability in Subjects with Idiopathic Pulmonary Fibrosis". A37. Ild Therapy I. pp. A1493. doi:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1493. S2CID 225921518.

[1]

[2]

[3]

[4]